| Literature DB >> 30712258 |
Radhika Gudi1, Nicolas Perez2, Benjamin M Johnson1, M Hanief Sofi1, Robert Brown1, Songhua Quan2, Subha Karumuthil-Melethil2, Chenthamarakshan Vasu1.
Abstract
The dietary supplement and prebiotic values of β-glucan-rich products have been widely recognized and dietary approaches for modulating autoimmunity have been increasingly explored, we assess the impact of oral administration of high-purity yeast β-glucan (YBG) on gut immune function, microbiota and type 1 diabetes (T1D) using mouse models. Oral administration of this non-digestible complex polysaccharide caused a dectin-1-dependent immune response involving increased expression of interleukin-10 (IL-10), retinaldehyde dehydrogenase (Raldh) and pro-inflammatory cytokines in the gut mucosa. YBG-exposed intestinal dendritic cells induced/expanded primarily Foxp3+ , IL-10+ and IL-17+ T cells, ex vivo. Importantly, prolonged oral administration of low-dose YBG at pre-diabetic stage suppressed insulitis and significantly delayed the appearance of T1D in non-obese diabetic (NOD) mice. Further, prolonged treatment with YBG showed increased Foxp3+ T-cell frequencies, and a significant change in the gut microbiota, particularly an increase in the abundance of Bacteroidetes and a decrease in the Firmicute members. Oral administration of YBG, together with Raldh-substrate and β-cell antigen, resulted in better protection of NOD mice from T1D. These observations suggest that YBG not only has a prebiotic property, but also an oral tolerogenic-adjuvant-like effect, and these features could be exploited for modulating autoimmunity in T1D.Entities:
Keywords: autoimmunity; gut microbiota; immune modulation; immune regulation; type 1 diabetes; yeast β-glucan
Mesh:
Substances:
Year: 2019 PMID: 30712258 PMCID: PMC6459770 DOI: 10.1111/imm.13048
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397